TD Cowen Maintains Hold on DarioHealth, Lowers Price Target to $8
TD Cowen analyst Charles Rhyee maintains DarioHealth (NASDAQ:DRIO) with a Hold and lowers the price target from $11 to $8.
Read original at benzingaStocks · News reference
Alliance Global Partners Initiates Coverage On DarioHealth with Buy Rating, Announces Price Target of $12
Alliance Global Partners analyst Scott Henry initiates coverage on DarioHealth (NASDAQ:DRIO) with a Buy rating and announces Price Target of $12.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 19, 2026, 3:45 PM
- Checked
- Aug 19, 2026, 3:45 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
DarioHealth Q2 Adj. EPS $(0.72) Beats $(1.22) Estimate, Sales $5.177M Miss $5.923M Estimate
DarioHealth (NASDAQ:DRIO) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(1.22) by 40.98 percent. This is a 82.44 percent increase over losses of $(4.10) per share from the
Read original at benzingaDarioHealth Launches GLP-1 Program, With Commercial Availability Expected Fall 2026, With Revenue Contribution From Late 2026 And Ramping Through 2027
Read original at benzinga